- Investing.com
तुलना करने के लिए मीट्रिक्स | SRZN | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधSRZNपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.8x | −691.9x | −0.4x | |
PEG अनुपात | 0.02 | −7.00 | 0.00 | |
क़ीमत/बुक | −1.0x | 9.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 36.0x | 26.0x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 84.9% | 105.3% | 58.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.3% | 8.3% | अनलॉक करें |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.